Maternal uniparental disomy of chromosome 21

disease
On this page

Also known as maternal uniparental disomy of chromosome type 21UPD(21)mat

Summary

Maternal uniparental disomy of chromosome 21 (MONDO:0019918) is a disease. A subtype of uniparental disomy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 12

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families2WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

12 HPO clinical features (Orphanet curated; top 12 by frequency):

HPO IDTermFrequency
HP:6000197Reduced muscle phosphoglycerate mutase activityVery frequent (80-99%)
HP:0002913MyoglobinuriaFrequent (30-79%)
HP:0003236Elevated circulating creatine kinase concentrationFrequent (30-79%)
HP:0003326MyalgiaFrequent (30-79%)
HP:0003546Exercise intoleranceFrequent (30-79%)
HP:0003710Exercise-induced muscle crampsFrequent (30-79%)
HP:0100301Muscle fiber tubular inclusionsFrequent (30-79%)
HP:0001324Muscle weaknessOccasional (5-29%)
HP:0001919Acute kidney injuryOccasional (5-29%)
HP:0008942Acute rhabdomyolysisOccasional (5-29%)
HP:0003457EMG abnormalityExcluded (0%)
HP:0040129Abnormal nerve conduction velocityExcluded (0%)

Identifiers

Disease identifiers

FieldValue
Canonical namematernal uniparental disomy of chromosome 21
Mondo IDMONDO:0019918
Orphanet96187
ICD-11553200266
UMLSC5190523
MedGen1673526
GARD0019337
Is cancer (heuristic)no

Also known as: maternal uniparental disomy of chromosome type 21 · UPD(21)mat

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › chromosomal disorder › uniparental disomy › maternal uniparental disomy of chromosome 21

Related subtypes (26): paternal uniparental disomy of chromosome 14, silver-Russell syndrome due to maternal uniparental disomy of chromosome 11, paternal uniparental disomy of chromosome 1, maternal uniparental disomy of chromosome 1, maternal uniparental disomy of chromosome X, paternal uniparental disomy of chromosome X, mosaic genome-wide paternal uniparental disomy, maternal uniparental disomy of chromosome 2, maternal uniparental disomy of chromosome 4, maternal uniparental disomy of chromosome 6, silver-Russell syndrome due to maternal uniparental disomy of chromosome 7, maternal uniparental disomy of chromosome 9, maternal uniparental disomy of chromosome 14, maternal uniparental disomy of chromosome 16, maternal uniparental disomy of chromosome 20, maternal uniparental disomy of chromosome 22, paternal uniparental disomy of chromosome 5, paternal uniparental disomy of chromosome 6, paternal uniparental disomy of chromosome 7, Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11, paternal uniparental disomy of chromosome 20, paternal uniparental disomy of chromosome 21, maternal uniparental disomy of chromosome 13, Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15, Angelman syndrome due to paternal uniparental disomy of chromosome 15, paternal uniparental disomy of chromosome 13

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.